Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Communications (1)
Nature (1)
Nature Medicine (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Cell biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–3 of 3 results

Advanced filters: Author: Jacqueline Galeas Clear advanced filters

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer

KRAS mutations are frequent in pancreatic ductal adenocarcinoma, leading to bad prognosis and resistance to targeted therapies. Here, the authors show that LIF expression is specifically induced by KRAS and constitutes a potential target to treat these KRAS-mutated cancers.

Man-Tzu Wang
Nicole Fer
Frank McCormick
ResearchOpen Access11 Jul 2019
Nature Communications

Volume: 10, P: 1-10
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Nongenetic activation of Aurora kinase A in the majority of patients with non-small-cell lung cancer mediates adaptive resistance to EGFR inhibition and offers an opportunity for combination treatment.

Khyati N. Shah
Roma Bhatt
Sourav Bandyopadhyay
Research26 Nov 2018
Nature Medicine

Volume: 25, P: 111-118
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Cancer persister cells, which survive cytotoxic treatments, are shown to be sensitive to inhibition of the lipid hydroperoxidase GPX4.

Matthew J. Hangauer
Vasanthi S. Viswanathan
Michael T. McManus
Research01 Nov 2017
Nature

Volume: 551, P: 247-250